Comprehensive Dermatologic Drug Therapy

1. Part I. Introduction - p. P1 2. 1. Basic Principles of Pharmacology - p. 1 3. 2. Principles for Maximizing the Safety of Dermatologic Drug Therapy - p. 12 4. 3. Polymorphisms: Why Individual Drug Responses Vary - p. 21 5. 4. Adherence to Drug Therapy - p. 34 6. 5. Medical Decision Making - p. 40 7. Part II. Important Drug Regulatory Issues - p. P2 8. 6. The FDA Drug Approval Process - p. 49 9. 7. Pharmacovigilance: Verifying that Drugs Remain Safe - p. 54 10. 8. Drugs Taken Off the Market: Important Lessons Learned - p. 62 11. Part III. Systemic Drugs for Infectious Diseases - p. P3 12. 9. Systemic Antibacterial Agents - p. 69 13. Introduction - p. 70 14. Penicillins - p. 70 15. Cephalosporins - p. 75 16. β-Lactam and β-Lactamase Inhibitor Combinations - p. 77 17. Other Systemic Antibacterials that Inhibit Cell Wall Synthesis - p. 77 18. Macrolides - p. 78 19. Fluoroquinolones - p. 81 20. Tetracyclines - p. 82 21. Rifampin and Other Rifamycins - p. 89 22. Folate Synthesis Inhibitors - p. 93 23. Lincosamides - p. 95 24. Oxazolidinones - p. 96 25. Special Topics - p. 96 26. 10. Systemic Antifungal Agents - p. 99 27. 11. Systemic Antiviral Agents - p. 114 28. 12. Systemic Antiparasitic Agents - p. 126 29. Part IV. Systemic Immunomodulatory Drugs - p. P4 30. 13. Systemic Corticosteroids - p. 133 31. 14. Methotrexate - p. 156 32. 15. Azathioprine - p. 169 33. 16. Mycophenolates - p. 178 34. 17. Cyclosporine - p. 187 35. 18. Phosphodiesterase-4 and Janus Kinase Inhibitors - p. 199 36. 19. Cytotoxic Agents - p. 209 37. 20. Dapsone - p. 222 38. 21. Antimalarial Agents - p. 234 39. 22. Systemic Retinoids - p. 245 40. Part V. Drugs Used in Conjunction with UV or Visible Light - p. P5 41. 23. Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities - p. 263 42. 24. Extracorporeal Photochemotherapy (Photopheresis) - p. 271 43. 25. Photodynamic Therapy - p. 280 44. Part VI. Biologic Therapeutics - p. P6 45. 26. Tumor Necrosis Factor Inhibitors - p. 287 46. 27. Interleukin 12/23 Inhibitors - p. 302 47. 28. Interleukin 17 Inhibitors - p. 312 48. 29. Interleukin 23 Inhibitors - p. 321 49. 30. Rituximab - p. 330 50. 31. Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others - p. 339 51. Part VII. Miscellaneous Systemic Drugs - p. P7 52. 32. Antihistamines - p. 349 53. 33. Vasoactive and Antiplatelet Agents - p. 358 54. 34. Antiandrogens and Androgen Inhibitors - p. 366 55. 35. Psychotropic Agents - p. 382 56. 36. Intravenous Immunoglobulin Therapy - p. 397 57. 37. Systemic Anticancer Agents: Dermatologic Indications and Adverse Events - p. 406 58. 38. Hedgehog Pathway Inhibitors - p. 419 59. 39. Drugs for the Skinternist - p. 430 60. 40. Miscellaneous Systemic Drugs - p. 446 61. Introduction - p. 446 62. Anticholinergic Agents—Glycopyrrolate and Oxybutynin - p. 446 63. Attenuated Androgens—Danazol - p. 447 64. Biotin - p. 447 65. Clofazimine - p. 448 66. Colchicine - p. 450 67. Fumaric Acid Esters - p. 452 68. Niacinamide - p. 452 69. Nonsteroidal Anti-inflammatory Drugs - p. 454 70. Pharmacology - p. 454 71. Clinical Use - p. 454 72. Off-Label Dermatologic Uses - p. 454 73. Adverse Effects - p. 455 74. Penicillamine - p. 455 75. Potassium Iodide - p. 456 76. Thalidomide - p. 457 77. Vitamin E - p. 462 78. Zinc Sulfate - p. 462 79. Part VIII. Topical Drugs for Infectious Diseases - p. P8 80. 41. Topical Antibacterial Agents - p. 465 81. 42. Topical Antifungal Agents - p. 480 82. 43. Topical and Intralesional Antiviral Agents - p. 493 83. 44. Topical Antiparasitic Agents - p. 504 84. Part IX. Topical Immunomodulatory Drugs - p. P9 85. 45. Topical Corticosteroids - p. 511 86. 46. Topical Retinoids - p. 528 87. 47. Topical and Intralesional Chemotherapeutic Agents - p. 541 88. 48. Topical Calcineurin Inhibitors - p. 549 89. 49. Topical Vitamin D3 - p. 557 90. Part X. Miscellaneous Topical Drugs - p. P10 91. 50. Sunscreens - p. 565 92. 51. Therapeutic Shampoos - p. 576 93. 52. α-Hydroxy Acids - p. 585 94. 53. Chemical Peels - p. 592 95. 54. Products for the Care of Chronic Wounds - p. 597 96. 55. Agents Used for Treatment of Hyperkeratosis - p. 607 97. 56. Irritants and Allergens: When to Suspect Topical Therapeutic Agents - p. 617 98. 57. Miscellaneous Topical Agents - p. 624 99. Part XI. Injectable and Mucosal Routes of Drug Administration - p. P11 100. 58. Local Anesthetics - p. 631 101. 59. Injectable Dermal and Subcutaneous Fillers - p. 650 102. 60. Botulinum Toxin Injections - p. 656 103. 61. Oral Mucosal Therapeutics - p. 665 104. Part XII. Major Adverse Effects From Systemic Drugs - p. P12 105. 62. Hepatotoxicity of Dermatologic Drug Therapy - p. 677 106. 63. Hematologic Toxicity of Drug Therapy - p. 689 107. 64. Drug-Induced Malignancy - p. 700 108. 65. Dermatologic Drugs During Pregnancy and Lactation - p. 710 109. 66. Drug Interactions - p. 725 110. 67. Cutaneous Drug Reactions With Systemic Features - p. 743 111. Part XIII. Special Pharmacology and Therapeutics Topics - p. P13 112. 68. Informed Consent and Risk Management - p. 753 113. 69. Compounding in Dermatology - p. 759 114. 70. Dermatologic Drug Therapy in Children - p. 767 115. Appendix I. Core Questions for Understanding Systemic Dermatologic Drugs - p. 777 116. Appendix II. The Most Potentially Serious Drug Interactions - p. 784 117. Index - p. 787